
Biocytogen and IDEAYA Advance Innovative Cancer Therapy with First Dosing of IDE034
First Patient Dosed in Phase 1 Trial of IDE034, a Bispecific B7H3/PTK7 TOP1 ADC Why is the development of new cancer therapies so critical in today’s healthcare landscape? Biocytogen Pharmaceuticals…












